Welcome to our dedicated page for Alumis news (Ticker: ALMS), a resource for investors and traders seeking the latest updates and insights on Alumis stock.
Alumis Inc (ALMS) is a clinical-stage biopharmaceutical company advancing precision oral therapies for immune-mediated diseases through its proprietary data analytics platform. This page provides investors and industry stakeholders with centralized access to validated updates on the company’s clinical programs, regulatory milestones, and scientific advancements.
Track developments across Alumis’ pipeline including ESK-001, a selective TYK2 inhibitor in Phase 3 trials for plaque psoriasis and lupus, and A-005, a CNS-penetrant candidate targeting neuroinflammatory conditions. Our news collection covers essential updates such as clinical trial results, partnership announcements, and regulatory submissions while maintaining compliance with financial disclosure standards.
Key content categories include trial progression updates, peer-reviewed data publications, executive leadership changes, and strategic collaborations. All materials are curated to provide actionable insights without speculative commentary or investment recommendations.
Bookmark this page for streamlined access to Alumis’ latest developments in transforming autoimmune disease treatment through precision-targeted therapies. Verify information through primary sources via linked press releases and official filings where available.
Alumis (Nasdaq: ALMS) has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE). The trial has enrolled 408 patients who will receive ESK-001 or placebo for 48 weeks.
The study will evaluate the drug's efficacy in treating moderately-to-severely active, autoantibody-positive SLE, with topline data expected in Q3 2026. The primary endpoint will measure disease activity improvements using the BICLA assessment at Week 48. The company reports that ESK-001 has shown promising results in their psoriasis program, demonstrating full target inhibition and general tolerability.
Alumis (Nasdaq: ALMS), a late-stage biopharma company focused on immune-mediated diseases, has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary. Pangali, who previously served as Senior Vice President, Legal at Alumis, succeeds Sara Klein following her retirement.
In her new role, Pangali will oversee all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory. She brings significant experience from her previous positions at ACELYRIN, Snapdocs, and Principia Biopharma, where she held senior legal roles. Her background includes leading legal affairs through significant corporate events, including IPOs and mergers.
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO, Martin Babler, will deliver a presentation on June 4, 2025, at 3:10 p.m. ET. Interested parties can access a live webcast of the presentation through the "Investors" section of the Alumis website, under the "Events" page. The webcast recording will remain available for replay on the company's website for 90 days following the event.
Alumis Inc. (NASDAQ: ALMS) has completed its merger with ACELYRIN, Inc., creating a leading clinical-stage biopharma company focused on immune-mediated diseases. Under the merger terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share. ACELYRIN's stock has been delisted from NASDAQ.
The merger significantly strengthens Alumis' balance sheet, extending its cash runway into 2027. The combined company aims to advance its late-stage portfolio through multiple planned key data readouts. Morgan Stanley advised Alumis, while Guggenheim Securities advised ACELYRIN in the transaction.
Alumis Inc. (ALMS) stockholders have approved all proposals necessary for the pending merger with ACELYRIN, INC. (SLRN). The merger, announced at a Special Meeting of Stockholders, is expected to close in Q2 2025, subject to customary closing conditions. CEO Martin Babler expressed gratitude for stockholder support and highlighted that the merger would strengthen the company's financial foundation to advance breakthroughs in immune-mediated diseases. Alumis will file the final voting results in a Form 8-K with the SEC.
Alumis (NASDAQ: ALMS) and ACELYRIN have announced an amended merger agreement with revised ownership terms. Under the new agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share, resulting in Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning 48% of the combined company.
The merger aims to create a leading clinical-stage immunology company with enhanced financial flexibility. The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024, with funding expected to last into 2027. The transaction has received unanimous approval from both companies' boards, with stockholder voting agreements already secured from 62% of Alumis and 24% of ACELYRIN shareholders.
Special stockholder meetings are scheduled for May 13, 2025, with the transaction expected to close in Q2 2025, subject to stockholder approval and customary closing conditions.
Alumis (NASDAQ: ALMS) and ACELYRIN have filed a definitive proxy statement for their proposed merger, scheduled for completion in Q2 2025. The merger will create a late-stage clinical biopharma company focused on immune-mediated diseases with a pro forma cash position of $737 million, providing runway into 2027.
Key pipeline milestones include Phase 3 ONWARD trials for ESK-001 in psoriasis (1Q 2026), Phase 2b LUMUS trial in lupus (2026), Phase 2 trial initiation for A-005 in MS, and development of lonigutamab for thyroid eye disease.
Under the agreement, ACELYRIN stockholders will receive 0.4274 shares of Alumis common stock per share, resulting in Alumis stockholders owning 55% and ACELYRIN stockholders owning 45% of the combined company. Special stockholder meetings will be held virtually on May 13, 2025, with a record date of April 1, 2025.
Alumis (NASDAQ: ALMS) and Kaken Pharmaceutical have announced a collaboration and licensing agreement for ESK-001, a next-generation oral TYK2 inhibitor, in Japan. The deal includes $40 million in upfront and near-term co-development payments during 2025-2026, with potential for additional $140 million in milestone and field option payments, plus tiered royalties ranging from low double-digits to twenties on net sales.
Kaken will handle clinical development, regulatory approvals, and commercialization of ESK-001 in Japan for dermatology indications, with an option to expand into rheumatological and gastrointestinal diseases. The company will also contribute to global development costs, while Alumis retains rights in all other regions. The partnership builds on ESK-001's positive Phase 2 clinical data.
FAQ
What is the current stock price of Alumis (ALMS)?
What is the market cap of Alumis (ALMS)?
